WorldCat Identities

Peto, Richard 1943-

Overview
Works: 52 works in 111 publications in 4 languages and 1,502 library holdings
Genres: Conference papers and proceedings  Biography 
Roles: Editor, Author, Other, Thesis advisor
Publication Timeline
.
Most widely held works by Richard Peto
The causes of cancer : quantitative estimates of avoidable risks of cancer in the United States today by Richard Doll( Book )

20 editions published between 1981 and 1989 in English and held by 399 WorldCat member libraries worldwide

Our report consists of a review of the evidence that cancer is largely an avoidable disease, a review of recent upward or downward trends in the onset rates of various types of cancer, a review of our reasons for preferring an epidemiological rather than a laboratory-based approache to the quantitative attribution of human risk, and then a dozen separate sections, one on each of the possible ways or groups of ways of avoiding cancer. The final section then summarizes and brings together our principal conclusions. [Authors]
Mortality from smoking in developed countries, 1950-2000 : indirect estimates from national vital statistics by Richard Peto( Book )

10 editions published in 1994 in English and Undetermined and held by 353 WorldCat member libraries worldwide

It is well recognized that smoking is the leading cause of avoidable death in developed countries. Recent evidence suggests that, although not publicly, the tobacco industry recognized the health hazards of smoking decades ago. Nevertheless, more seems to be needed to ban smoking from our society completely. The current book by Richard Peto and colleagues from World Health Organization, the American Cancer Society, and the Imperial Cancer Research Fund tries to contribute to the prevention of smoking by an ambitious attempt to quantify the magnitude of the smoking epidemic. In 1992, a first overall estimate of smoking-attributable mortality in developed populations was published in Lancet. The book presents these results in much more detail for 46 developed countries separately and for Organization for Economic Cooperation and Development (OECD) countries, former Socialist economies, and the European Union countries
Quantification of occupational cancer by Banbury Center( Book )

6 editions published in 1981 in English and held by 230 WorldCat member libraries worldwide

Viral etiology of cervical cancer by Banbury Center( Book )

8 editions published in 1986 in English and held by 182 WorldCat member libraries worldwide

Tobacco : the growing epidemic : proceedings of the tenth World Conference on Tobacco or Health, 24-28 August 1997, Beijing, China by Rushan Lu( )

2 editions published in 2000 in English and held by 44 WorldCat member libraries worldwide

This book contains the full proceedings of the Tenth World Conference on Tobacco or Health, held 24-28 August 1997 in Beijing, China, and hosted by the Chinese Association on Smoking and Health and the Chinese Medical Association. Tobacco is now causing a worldwide epidemic of premature death and disability, affecting first men and then women in developed countries, and now increasingly affecting developing countries. The theme "Tobacco: The Growing Epidemic" was chosen to reflect the increasingly global nature of the problem
Las causas del cáncer : valoración cuantitativa actual de los riesgos evitables de cáncer en Estados Unidos by Richard Doll( Book )

2 editions published in 1989 in Spanish and held by 12 WorldCat member libraries worldwide

Pioneering physician : the life of Charles Fletcher 1911-1995 by Max Blythe( Book )

2 editions published in 2016 in English and held by 9 WorldCat member libraries worldwide

Atlas: adjuvant tamoxifen longer against shorter by Richard Peto( Book )

7 editions published between 1997 and 2000 in English and held by 8 WorldCat member libraries worldwide

World-wide, more than 1 million women with early breast cancer take adjuvant tamoxifen. But, there is substantial uncertainty about the optimal duration of treatment, and in particular!, as to whether tamoxifen should be stopped after 5 years, or continued for longer-this has not been addressed adequately in the other small trials of this question. ATLAS is an international trial designed to assess this reliably. If the study demonstrates that longer treatment confers additional benefit, several thousands of deaths could be avoided each year if women are treated accordingly. With funding from the US Army BCRP, a world-wide - collaboration has been established. By early 1999, ATLAS will be the largest ever trial of tamoxifen duration. 32 countries are participating, 330 centres have ethics approval, 246 centres are randomizing. By 30111/1998, 3500 women had entered the study. Accrual should increase as more centres obtain ethics - approval and the 10-20,000 accrual target should be reached early in the millenium. 3 follow-up cycles have been undertaken demonstrating good treatment compliance in both study arms, and reliable and complete acquisition of follow-up data. Additional funding is required to maintain the collaboration to achieve the accrual target and long-term follow-up
Le cause del cancro : prospettive di prevenzione by Richard Doll( Book )

3 editions published in 1983 in Italian and held by 5 WorldCat member libraries worldwide

Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments( Book )

1 edition published in 1980 in English and held by 5 WorldCat member libraries worldwide

The Growing Epidemic : Proceedings of the Tenth World Conference on Tobacco or Health, 24-28 August 1997, Beijing, China by Rushan Lu( )

1 edition published in 2000 in English and held by 5 WorldCat member libraries worldwide

Halving premature death : is it realistic? by Richard Peto( Visual )

3 editions published between 2002 and 2006 in English and held by 4 WorldCat member libraries worldwide

Tobacco : a major international health hazard by D.G ZARIDZE( Book )

2 editions published in 1986 in English and held by 4 WorldCat member libraries worldwide

Tobacco : a major international health hazard : proceedings of an international meeting( Book )

1 edition published in 1986 in English and held by 3 WorldCat member libraries worldwide

Risk thresholds for alcohol consumption combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies by Angela M Wood( )

2 editions published in 2018 in English and held by 2 WorldCat member libraries worldwide

Background: Low-risk limits recommended for alcohol consumption vary substantially across different national guidelines. To define thresholds associated with lowest risk for all-cause mortality and cardiovascular disease, we studied individual-participant data from 599 912 current drinkers without previous cardiovascular disease. Methods: We did a combined analysis of individual-participant data from three large-scale data sources in 19 high-income countries (the Emerging Risk Factors Collaboration, EPIC-CVD, and the UK Biobank). We characterised dose-response associations and calculated hazard ratios (HRs) per 100 g per week of alcohol (12.5 units per week) across 83 prospective studies, adjusting at least for study or centre, age, sex, smoking, and diabetes. To be eligible for the analysis, participants had to have information recorded about their alcohol consumption amount and status (ie, non-drinker vs current drinker), plus age, sex, history of diabetes and smoking status, at least 1 year of follow-up after baseline, and no baseline history of cardiovascular disease. The main analyses focused on current drinkers, whose baseline alcohol consumption was categorised into eight predefined groups according to the amount in grams consumed per week. We assessed alcohol consumption in relation to all-cause mortality, total cardiovascular disease, and several cardiovascular disease subtypes. We corrected HRs for estimated long-term variability in alcohol consumption using 152 640 serial alcohol assessments obtained some years apart (median interval 5.6 years [5th-95th percentile 1.04-13.5]) from 71 011 participants from 37 studies. Findings: In the 599 912 current drinkers included in the analysis, we recorded 40 310 deaths and 39 018 incident cardiovascular disease events during 5.4 million person-years of follow-up. For all-cause mortality, we recorded a positive and curvilinear association with the level of alcohol consumption, with the minimum mortality risk around or below 100 g per week. Alcohol consumption was roughly linearly associated with a higher risk of stroke (HR per 100 g per week higher consumption 1.14, 95% CI, 1.10-1.17), coronary disease excluding myocardial infarction (1.06, 1.00-1.11), heart failure (1.09, 1.03-1.15), fatal hypertensive disease (1.24, 1.15-1.33); and fatal aortic aneurysm (1.15, 1.03-1.28). By contrast, increased alcohol consumption was loglinearly associated with a lower risk of myocardial infarction (HR 0.94, 0.91-0.97). In comparison to those who reported drinking >0-<= 100 g per week, those who reported drinking >100-<= 200 g per week, >200-<= 350 g per week, or >350 g per week had lower life expectancy at age 40 years of approximately 6 months, 1-2 years, or 4-5 years, respectively. Interpretation: In current drinkers of alcohol in high-income countries, the threshold for lowest risk of all-cause mortality was about 100 g/week. For cardiovascular disease subtypes other than myocardial infarction, there were no clear risk thresholds below which lower alcohol consumption stopped being associated with lower disease risk. These data support limits for alcohol consumption that are lower than those recommended in most current guidelines
Demokracja jest zdrowsza : cud zdrowotny nad Wisłą by W Zatoński( Book )

1 edition published in 2002 in Polish and held by 2 WorldCat member libraries worldwide

20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years( )

1 edition published in 2017 in English and held by 2 WorldCat member libraries worldwide

BACKGROUND: The administration of endocrine therapy for 5 years substantially reduces recurrence rates during and after treatment in women with early-stage, estrogen-receptor (ER)-positive breast cancer. Extending such therapy beyond 5 years offers further protection but has additional side effects. Obtaining data on the absolute risk of subsequent distant recurrence if therapy stops at 5 years could help determine whether to extend treatment. METHODS: In this meta-analysis of the results of 88 trials involving 62,923 women with ER-positive breast cancer who were disease-free after 5 years of scheduled endocrine therapy, we used Kaplan-Meier and Cox regression analyses, stratified according to trial and treatment, to assess the associations of tumor diameter and nodal status (TN), tumor grade, and other factors with patients' outcomes during the period from 5 to 20 years. RESULTS: Breast-cancer recurrences occurred at a steady rate throughout the study period from 5 to 20 years. The risk of distant recurrence was strongly correlated with the original TN status. Among the patients with stage T1 disease, the risk of distant recurrence was 13% with no nodal involvement (T1N0), 20% with one to three nodes involved (T1N1-3), and 34% with four to nine nodes involved (T1N4-9); among those with stage T2 disease, the risks were 19% with T2N0, 26% with T2N1-3, and 41% with T2N4-9. The risk of death from breast cancer was similarly dependent on TN status, but the risk of contralateral breast cancer was not. Given the TN status, the factors of tumor grade (available in 43,590 patients) and Ki-67 status (available in 7692 patients), which are strongly correlated with each other, were of only moderate independent predictive value for distant recurrence, but the status regarding the progesterone receptor (in 54,115 patients) and human epidermal growth factor receptor type 2 (HER2) (in 15,418 patients in trials with no use of trastuzumab) was not predictive. During the study period from 5 to 20 years, the absolute risk of distant recurrence among patients with T1N0 breast cancer was 10% for low-grade disease, 13% for moderate-grade disease, and 17% for high-grade disease; the corresponding risks of any recurrence or a contralateral breast cancer were 17%, 22%, and 26%, respectively. CONCLUSIONS: After 5 years of adjuvant endocrine therapy, breast-cancer recurrences continued to occur steadily throughout the study period from 5 to 20 years. The risk of distant recurrence was strongly correlated with the original TN status, with risks ranging from 10 to 41%, depending on TN status and tumor grade. (Funded by Cancer Research UK and others.)
 
moreShow More Titles
fewerShow Fewer Titles
Audience Level
0
Audience Level
1
  Kids General Special  
Audience level: 0.57 (from 0.45 for Mortality ... to 0.98 for Le cause d ...)

Viral etiology of cervical cancer
Covers
Tobacco : the growing epidemic : proceedings of the tenth World Conference on Tobacco or Health, 24-28 August 1997, Beijing, China
Alternative Names
Peto R.

Peto, R. 1943-

Peto, R. (Richard), 1943-

Richard Peto britischer Statistiker und Epidemiologe

Richard Peto Brits epidemioloog

Richard Peto English statistician and epidemiologist

Пито Р.

Ричард Пето

Річард Пето

ريتشارد بيتو

Languages